AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05038748 — intervention group
Intervention type: OTHER
Intervention: ASD diagnosis
Description: Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS)
Study NCT02495740 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Commuting to work
Description: Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
Study NCT02495740 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Commuting to work
Description: Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
Study NCT01726413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 17356
Study NCT04476472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omnipod Horizon™ Automated Glucose Control System
Description: The Omnipod Horizon™ Automated Glucose Control System will provide automated insulin delivery.
Study NCT04225403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based motivational interviewing for smoking cessation
Description: The motivational brief intervention is known by the acronym 5 R and lasts about 5-10 minutes. It is an approach based on the principles of motivational interviewing and develops the intervention in five short steps:~* Relevance. Help patients identify why personal reasons may be relevant to quitting smoking.~* Risks. Help identify what negative consequences tobacco use has.~* Rewards. Help identify potential benefits of quitting smoking.~* Resistors. Help patients identify barriers to smoking cessation, which can often include fear of withdrawal symptoms, failure, wainweight, face social situations, etc.~* Repeat. Repeat the intervention at 3 months if you do not advance at the stage of change.
Study NCT02141321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01726413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Study NCT05689138 — intervention group
Intervention type: OTHER
Intervention: Oral and Fecal Sample Collection
Description: No interventions
Study NCT01430390 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological/Genetically Modified T cells
Description: Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells. A fixed CAR EBV-CTL dose (3x106 EBV-CTLs/kg) which has been demonstrated to be the ideal manufacturing dose allowing for multiple infusions and potential for multiple patient treatments per cell line generated will be used for all patients on this trial. Cohorts will be determined separately but cohort 3 will not begin to accrue until cohort 2 has treated three (3) patients without a DLT. Each patient is eligible for up to three (3) infusions.
Study NCT01430390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-based chemotherapy
Description: Cyclophosphamide-based chemotherapy regimen will be the preferred conditioning chemotherapy prior to CAR T cell infusion for patients with CD19+ malignancy in cohort 1. Recommended chemotherapy regimen consists of single agent Cyclophosphamide at a dose of 3000 mg/m2/dose IV over 1 hour or 1500mg/m2/dose x 2 doses given daily over 1 hour given for 2 days (patients may received reduced dose of cyclophosphamide based on the clinical status of the patient at discretion of the treating physician and with written approval by the MSKCC PI of this study). Alternative cyclophosphamide or non-cyclophosphamide-based regimens based on the clinical status of the patient, disease burden, and likely-hood of response may be used at the discretion of the treating physician with written approval by MSKCC PI of the study. Conditioning chemotherapy will not be given prior to infusions # 2 and #3.
Study NCT04518501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic trioxide Tablet +Fuzuloparib Capsules
Description: Arsenic trioxide Tablet : 0.27\*9 tid po consecutive 21 days with 1 week rest． Fuzuloparib Capsules: 150 mg bid po
Study NCT03705234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran
Description: Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
Study NCT03705234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as sterile normal saline (0.9% sodium chloride in water for injection).
Study NCT04128709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urodynamics Testing
Description: The non-invasive device connects to the end of urinary catheter that the patient uses for routine daily catheterization. Once urine flows into the device the patient presses a single button in order to obtain a pressure measurement which is recorded and stored in the device along with the time and date. The measurement(s) can later be transmitted wirelessly to a smart phone that contains an app for the device.
Study NCT01604317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation-torso plastic bag
Description: Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
Study NCT01604317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resuscitation-partial-head plastic bag
Description: Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
Study NCT01813383 — intervention group
Intervention type: OTHER
Intervention: There is not any intervention
Study NCT01210820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFS™ Femtosecond Laser System
Description: intrastromal arcuate cuts made with iFS™ femtosecond laser
Study NCT02210806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A006 DPI
Description: Single dose 110 mcg, 1 inhalation
Study NCT02210806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A006 DPI
Description: Single dose 220 mcg, 1 inhalation
Study NCT02210806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo, 1 inhalation
Study NCT02210806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 1 inhalation
Study NCT02210806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil® MDI
Description: Single dose 90 mcg, 2 inhalations
Study NCT01875250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F (Fowlpox)/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
Study NCT01875250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V (Vaccinia)/TRICOM
Description: A recombinant vaccinia virus vector vaccine containing the genes for human prostate specific antigen (PSA) and three co-stimulatory molecules.
Study NCT01875250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi)
Description: An androgen receptor inhibitor.
Study NCT02139696 — intervention group
Intervention type: RADIATION
Intervention: PET and MRI
Description: Patients will be imaged using PET and MRI at baseline, and twice during treatment
Study NCT02273986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02273986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877
Study NCT02077426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regional Specific Training (RSTS)
Description: The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
Study NCT00867867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous fumarate
Description: 9.3 mg once per day, 6 days per week, for 9 months
Study NCT00867867 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric pyrophosphate
Description: 9.3 mg once per day, 6 days per week, for 9 months
Study NCT00867867 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9.3 mg once per day, 6 days per week, for 9 months
Study NCT01875848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: partial opioid agonist
Study NCT01875848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: opioid dose escalation
Description: up to 25% increase in patient's current opioid dose
Study NCT02952209 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Study NCT03720236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant bed preparation protocol
Description: This is the first surgical phase, we prepare the implant bed by using different increasing size drills.
Study NCT03720236 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant loading
Description: This is the second phase, based on prosthetic procedures, to design the crown over the dental implant
Study NCT00482729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
Study NCT00482729 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
Study NCT02328963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus : 0.75 bid, targeted to 3-8 ng/ml~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
Study NCT02328963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolic acid
Description: Mycophenolic acid :~1080 mg bid for one month, then 720 mg bid~Cyclosporin A :~CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.~Corticosteroids :~Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study~Basiliximab :Day 0: 20 mg ; Day 4: 20 mg
Study NCT00997321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
Study NCT01645423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium Tablets, 80 mg
Description: Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
Study NCT01758822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No endotracheal suction
Description: Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
Study NCT03064321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Insomnia Intervention
Description: The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
Study NCT03064321 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: Information on websites that are general health promoting
Study NCT02726919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clobazam
Description: Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
Study NCT03601546 — intervention group
Intervention type: OTHER
Intervention: Clinical examination
Description: Blood test and patient interview as for standard patient care
Study NCT01057381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.75 mcg/kg
Description: Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
Study NCT01057381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 50 mcg/kg
Description: Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
Study NCT01057381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 100 mcg/kg
Description: Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
Study NCT01057381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 1 mcg/kg
Description: Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
Study NCT00986453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade
Description: The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
Study NCT00986453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study NCT01148641 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: LNS
Description: Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days (crossover design) and thereafter, 20 g per day for 14 days.
Study NCT02113176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study NCT02113176 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Minocycline
Study NCT03153618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VALIDATE system
Description: Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
Study NCT04948957 — intervention group
Intervention type: DRUG
Intervention: Esmolol
Study NCT04948957 — intervention group
Intervention type: DRUG
Intervention: Nitroglycerin
Study NCT06132620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoston
Description: Fenmorphone (this product is a compound preparation, estradiol tablets contain estradiol 2mg; Estradiol dydrogesterone tablets contain estradiol 2 mg and dydrogesterone 10 mg).~Usage: 1 time/day: 1 tablet orally every day, every 28 days as a course of treatment.
Study NCT06132620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qingxin Zishen Decoction
Description: Qingxin Zi Kidney Decoction is a traditional Chinese medicine decoction, after regular decoction, 1 dose/day, divided into 2 doses.
Study NCT02980302 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cutaneous biopsy
Description: Under local anesthesia
Study NCT00997321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
Study NCT05178251 — intervention group
Intervention type: PROCEDURE
Intervention: appendectomy
Description: appendectomy for acute appendicitis
Study NCT00633126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftaroline
Description: Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
Study NCT03804398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compliance guided an optimal Positive End-Expiratory Pressure
Description: The study groups received an alveolar recruitment maneuver(increase inspiratory pressure to 30cmH2O for 10s) at the 10min after one-lung ventilation. After the alveolar recruitment maneuver,the study group titrate PEEP from 4cmH2O,increased in 2cmH2O steps and hold at each step for 1min,and the static pulmonary compliance(Cst) would be record.Optimal PEEP was determined until the maximal static pulmonary compliance was obtained.
Study NCT05360355 — intervention group
Intervention type: PROCEDURE
Intervention: total face reconstruction surgery and intraoperative indocyanine green angiography
Description: Patients with total facial scarring following burn injury were treated with monoblock pre-expanded prefabricated flaps for total face restoration. The opening of nostrils, oral and palpebral orifices, together with organ fabrication, were conducted under the guidance of intraoperative ICGA for hemodynamic evaluation.
Study NCT04392336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trust/Respect feedback
Description: This feedback includes information on the level of trust/respect that a consumer has for their clinician in addition to symptom feedback.
Study NCT03985748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAN
Description: Inhaled bronchodilators will be delivered using an AeroEclipse® II Breath Actuated Nebuliz (BAN)
Study NCT03985748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SN
Description: Inhaled bronchodilators will be delivered using a Standard Nebulizer (SN)
Study NCT03943953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information and Therapy Guides
Description: We have developed seven self-guided information and therapy guides (ITGs), for people with facial palsy and/or their friends or relatives. We have written these guides by drawing on interventions with a strong evidence-base in other populations, such as cognitive behavioural therapy, social skills training and acceptance and commitment therapy:~1. Facial palsy: Coping with the early stages.~2. Facial palsy: Coping with comments, questions and staring.~3. Facial palsy: Communicating with confidence.~4. Facial palsy: Managing anxiety.~5. Facial palsy: Managing your mood.~6. Facial palsy: Building your self-esteem.~7. Facial palsy: Advice for friends, family and partners.
Study NCT01835613 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biomarkers Measures
Description: At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
Study NCT03832439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Lactobacillus rhamnosus GG 10 billion cells and microcrystalline cellulose
Study NCT03832439 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: microcrystalline cellulose
Description: Placebo
Study NCT04786132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-motor training
Description: A DT training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups. The sessions included music that was unknown to the subjects but at the same time easy to learn, so that while they performed the motor tasks, they would memorize the songs.~The sessions were carried out by the main researcher who controlled both the technique of the exercises and motivated them to sing and perform a cognitive exercise.
Study NCT04786132 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor training
Description: A training protocol of 8 weeks duration was carried out, during 2 days a week, with a duration of 30 minutes each session divided into: warm-up (mobility and warm-up 5 '), main part (20') and cool down (5 'dynamic stretching). The main part consisted of a choreography divided into five measures of thirty-two beats each, in turn divided into four parts of eight movements, which included proprioception and balance exercises such as: squats, imbalances, lateral movements, front, standing on one leg, twist, etc. The sessions evolved from individual exercises, in pairs, in trios and finally in groups.